Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Knox, J J, Barrios, C H, Kim, T M, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, S Y, Flaig, T W, Page, R D, Beck, J T, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D, Motzer, R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Corrigenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290878/
https://www.ncbi.nlm.nih.gov/pubmed/29390043
http://dx.doi.org/10.1093/annonc/mdx807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290878/
https://www.ncbi.nlm.nih.gov/pubmed/29390043
http://dx.doi.org/10.1093/annonc/mdx807

Ejemplares similares